BioNTech SE (NASDAQ:BNTX) Shares Sold by Green Alpha Advisors LLC

Green Alpha Advisors LLC reduced its position in BioNTech SE (NASDAQ:BNTX) by 3.0% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 3,720 shares of the company’s stock after selling 117 shares during the period. Green Alpha Advisors LLC’s holdings in BioNTech were worth $424,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. TD Asset Management Inc boosted its holdings in shares of BioNTech by 6.1% in the second quarter. TD Asset Management Inc now owns 7,590 shares of the company’s stock valued at $612,000 after acquiring an additional 435 shares during the period. Choreo LLC acquired a new stake in BioNTech during the 2nd quarter worth $690,000. Daiwa Securities Group Inc. grew its position in BioNTech by 430.3% during the 2nd quarter. Daiwa Securities Group Inc. now owns 1,925 shares of the company’s stock worth $155,000 after purchasing an additional 1,562 shares during the last quarter. DekaBank Deutsche Girozentrale increased its stake in BioNTech by 3.8% in the second quarter. DekaBank Deutsche Girozentrale now owns 427,597 shares of the company’s stock valued at $34,533,000 after purchasing an additional 15,700 shares during the period. Finally, Virtu Financial LLC purchased a new stake in shares of BioNTech in the second quarter valued at about $1,586,000. 15.52% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on BNTX shares. Berenberg Bank assumed coverage on BioNTech in a research report on Tuesday, November 19th. They issued a “buy” rating and a $130.00 price target on the stock. HC Wainwright reissued a “buy” rating and issued a $150.00 target price on shares of BioNTech in a report on Monday, November 18th. Truist Financial initiated coverage on BioNTech in a report on Friday. They set a “buy” rating and a $172.00 price target for the company. Jefferies Financial Group raised shares of BioNTech from a “hold” rating to a “buy” rating and boosted their price objective for the company from $96.00 to $150.00 in a research note on Tuesday, September 17th. Finally, Wells Fargo & Company assumed coverage on shares of BioNTech in a research note on Wednesday, December 11th. They issued an “overweight” rating and a $170.00 target price for the company. Three research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $142.72.

BioNTech Trading Up 0.6 %

Shares of BioNTech stock opened at $122.85 on Monday. The company has a 50-day moving average of $114.30 and a two-hundred day moving average of $103.59. BioNTech SE has a 12-month low of $76.53 and a 12-month high of $131.49. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01. The stock has a market cap of $29.45 billion, a PE ratio of -58.50 and a beta of 0.18.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings data on Monday, November 4th. The company reported $0.81 earnings per share for the quarter, beating the consensus estimate of ($1.26) by $2.07. The firm had revenue of $1.24 billion during the quarter, compared to the consensus estimate of $514.08 million. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. BioNTech’s quarterly revenue was up 38.9% on a year-over-year basis. During the same period last year, the business posted $0.73 EPS. On average, research analysts anticipate that BioNTech SE will post -3.72 EPS for the current fiscal year.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.